Cancer diagnostics firm Pacific Edge (ASX:PEB) has unveiled its Q4 26 investor update, reporting a steady rise in laboratory throughput alongside critical advancements in global commercial coverage.
For the three months ended March, total laboratory throughput climbed 2.7% to 5,582 tests, a resilient performance achieved despite the operational friction of transitioning US customers from Cxbladder Detect to the Triage platform.
The company’s strategic momentum is increasingly tied to the US Medicare landscape.
Following a contractor advisory committee meeting in February, Pacific Edge expressed heightened confidence that Novitas will issue a positive draft local coverage determination by the end of Q2 27.
The regulatory optimism is bolstered by significant commercial wins; Cxbladder Triage has secured coverage from Blue Cross Blue Shield affiliates in North and South Carolina, collectively representing over 4 million covered lives.
Furthermore, Highmark has extended coverage to Cxbladder Monitor, adding an additional 7 million lives to the company’s US footprint.
International expansion remains a key driver of volume, with the APAC region seeing a 7.7% increase in test numbers.
Notable clinical adoptions include Singapore General Hospital and Townsville University Hospital in Queensland, both of which have integrated Cxbladder products into patient care pathways.
To safeguard its technological edge, the company also confirmed the filing of a patent cooperation treaty application for Triage Plus, ensuring long-term protection of its intellectual property as it scales globally.